Two-year Research Study Investigating How Well Semaglutide Works in People Suffering From Overweight or Obesity

NCT03693430 on ClinicalTrials.gov · last registry update 2023-07-06

Finished 29 January 2021, after enrolling 304 people. Primary outcome, as filed: Percentage Change From Baseline (Week 0) to Week 104 in Body Weight. semaglutide is already approved in the US for obesity, so this is asking a further question rather than establishing the drug works at all.

Status: COMPLETED
Phase: P3
Drug: semaglutide
Ozempic, Rybelsus, Wegovy
Sponsor: Novo Nordisk A/S
Sponsor type: Industry
Enrollment: 304
Started: 2018-10-05
Primary completion: 2021-01-29 actual

Observed history

No changes recorded since monitoring began on 2026-08-21. This record has held steady. If a reporting date moves, a status changes or enrollment is resized, it will appear here with the previous value alongside the new one.

Primary outcome

Percentage Change From Baseline (Week 0) to Week 104 in Body Weight

Conditions studied

Overweight · Obesity

Every field above is taken directly from the registry record. See all detected changes across the class, or the semaglutide page for this molecule’s full trial and approval history.